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Abstract 
Study Objective: To compare the effects of empiric vancomycin dosing regimens on attainment 
of optimal target trough concentrations in obese (body mass index [BMI] 30–40 kg/m2) and 
extremely obese (BMI ≥ 40 kg/m2) patients. 
Design: Retrospective cohort study. 
Data Source: National Veterans Affairs (VA) standardized databases. 
Patients: A total of 263 obese and 71 extremely obese (actual body weight range 72–244 kg in 
both groups) inpatients from all VA facilities nationally who had suspected methicillin-resistant 
Staphylococcus aureus pneumonia and were treated with vancomycin between 2002 and 2012. 
Measurements and Main Results: Patients with steady-state trough concentrations (measured 
≤ 2 hours before the next vancomycin dose) and no evidence of acute kidney injury prior to 
vancomycin initiation were included.  Logistic regression models were used to measure the 
effect of various vancomycin dosing regimens on attainment of optimal target trough 
concentrations (15–20 mg/L).  The mean total daily vancomycin dose was lower in obese 
versus extremely obese patients (2005 ± 736 vs. 2306 ± 934 mg, p<0.05).  The mean weight-
based daily dose was higher in obese patients (20 ± 7 vs. 17 ± 7 mg/kg/day, p<0.05).  In each 
group, about 20% of patients achieved optimal target trough concentrations.  In obese patients, 
the standard dose of approximately 30 mg/kg/day was appropriate for target trough 
concentration attainment (odds ratio [OR] 5.15, 95% confidence interval [CI] 1.69–15.64).  In 
extremely obese patients, a lower dose of 20–25 mg/kg/day was appropriate for target trough 
concentration attainment (OR 6.07, 95% CI 1.01–36.51). 
Conclusion: In this real-world study, we offer additional consideration of vancomycin dosing in 
obese and extremely obese patients.  Extremely obese patients may require a lower weight-
based daily dose than obese patients to reach target vancomycin trough concentrations. 
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According to the Centers for Disease Control and Prevention, the prevalence of obesity has 
increased over the past 20 years.1  More than one third of adults were obese in the United 
States in 2011-2012, which corresponds to over 78 million adults.1  This is concerning since 
obesity is associated with an increased risk of infection as well as increased morbidity and 
mortality.2-4 
For years, vancomycin, a glycopeptide antibiotic, has served as the standard of care for 
treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.5-7  Vancomycin 
exhibits a time-dependent antibacterial effect, and the area under the concentration-time curve 
to minimum inhibitory concentration (AUC/MIC) ratio is the best predictor of clinical efficacy.8  
Several studies suggest a target AUC/MIC ratio of ≥ 400 to achieve clinical effectiveness.9, 10  A 
vancomycin consensus review recommends maintaining serum trough concentrations between 
15-20 mg/L for complicated infections, such as pneumonia, to achieve target AUC/MIC ratios 
when the vancomycin MIC is ≤ 1 mg/L.8  Empiric vancomycin doses of 15-20 mg/kg of actual 
body weight (ABW) given every 8-12 hours are recommended for most patients with normal 
renal function to achieve these target serum concentrations.8  Additionally, a loading dose of 25-
30 mg/kg should be considered in seriously ill patients to achieve target concentrations quickly.8  
MRSA guidelines provide similar recommendations for vancomycin dosing and monitoring.11 
 Unfortunately, data are limited on the optimal dosing of vancomycin in obese patients.  
Moreover, it is presently unknown whether dosing recommendations should change based on 
different weight categories among obese patients.  Despite this, the vancomycin consensus 
review recommends that initial doses for obese patients should be based on ABW and that 
dosage adjustments be made based on serum trough levels to achieve optimal concentrations.8, 
12   No special recommendations for extremely obese patients are provided.8   
Optimizing vancomycin therapy in obese and extremely obese patients remains a 
challenge for clinicians.  As knowledge of antimicrobial pharmacokinetics is limited, and 
assessment of distribution and elimination are skewed in extremely obese patients, underdosing 
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or overdosing can easily occur.  A better understanding of the role of extreme patient weight on 
vancomycin dosing is needed.  As such, we sought to compare the effects of empiric 
vancomycin dosing regimens on attainment of optimal target trough concentrations in a real-
world cohort of obese and extremely obese patients. 
 
Methods 
Data Sources 
We used national Veterans Affairs (VA) standardized databases to obtain International 
Classification of Diseases, Ninth Revision, Clinical Modification diagnostic and procedure codes, 
microbiology results, pharmacy records for dispensings and barcode administration, and 
laboratory results.13 
 
Study Design and Patient Population 
We conducted a national retrospective cohort study of patients admitted to VA hospitals with 
positive MRSA cultures from a pulmonary site between 2002 and 2012, as described 
previously.13  Patients exposed to at least one day of therapy with intravenous vancomycin were 
selected for inclusion.  We included all obese patients with a body mass index (BMI) ≥ 30 
kg/m2.14 
We included patients with trough concentrations measured at steady state (i.e., after at 
least three vancomycin doses) and measured < 2 hours before the next vancomycin dose 
(Figure 1).8  Patients were included if they had no evidence of acute kidney injury (defined as an 
increase in serum creatinine concentration of 0.5 mg/dL or 50% prior to starting vancomycin).8  
Only the first trough level after the third vancomycin dose, which met our steady-state definition, 
was assessed.  Weight-based daily dosing categories were defined as follows: <10, 10-15, 15-
20, 20-25, 25-30, and ≥ 30 mg/kg/day. Target vancomycin trough concentrations were defined 
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as 15-20 mg/L.  Subtherapeutic concentrations were defined as < 15 mg/L, and 
supratherapeutic concentrations were defined as ≥ 20 mg/L.8   
 
Study Groups 
Patients were divided into two groups—obese (BMI 30-40 kg/m2) and extremely obese (BMI ≥ 
40 kg/m2)—based on the World Health Organization’s classification of obesity.14  
 
Statistical Analysis 
For categorical data, we used a Fisher exact or 2 test to evaluate differences between the 
obese and extremely obese groups.  For continuous data, we used a t test for normally 
distributed data and the Wilcoxon rank sum test for nonparametric data.  We used logistic 
regression models to measure the effect of initial maintenance weight-based daily vancomycin 
dosing regimens on target versus subtherapeutic and supratherapeutic trough attainment in 
obese and extremely obese patients, controlling for renal function.  Renal function was 
estimated by using the Cockcroft-Gault equation using adjusted body weight.  All analyses were 
performed using SAS statistical software (version 9.3; SAS Institute Inc., Cary, NC). 
 
Results 
We identified 334 vancomycin-treated patients from our original cohort with trough 
concentrations (Figure 1): 263 patients (78.7%) in the obese group and 71 patients (21.3%) in 
the extremely obese group (ABW range 72-244 kg in both groups) (Table 1).  The initial 
maintenance doses ranged widely (4-46 mg/kg/day or 500-6000 mg/day).  The most frequent 
daily maintenance dose was 2000 mg, which was dosed every 12 hours in most patients.  The 
initial daily maintenance vancomycin dose was significantly lower for obese patients versus the 
extremely obese (2005 ± 736.3 vs. 2306 ± 934.4 mg/day), however the weight-based daily dose 
was higher for obese patients (20 ± 7.4 vs. 17 ± 6.8mg/kg/day).  
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No significant differences in mean serum vancomycin trough concentrations were noted 
between obesity groups (Table 1).  In addition, the percentages of patients within the various 
trough level categories did not differ significantly between obesity groups (Figure 2). Only 19.4% 
(n=51) of the obese and 22.5% (n=16) of the extremely obese patients achieved target trough 
concentrations (15-20 mg/L).  Mean weight-based daily doses were significantly higher for the 
obese versus extremely obese patients when trough levels were 10-15 mg/L or 15-20 mg/L 
(Table 2).  At a target trough concentration of 15-20 mg/L, mean weight-based daily doses were 
about 21 and 14 mg/kg/day for obese and extremely obese patients, respectively.    
The most frequent daily dose for patients who achieved target trough concentrations 
was 2000 mg in both groups (Figure 3).  No significant difference was noted in attainment of 
target trough concentrations among those dosed at the standard dose of 1000 mg every 12 
hours versus those who were not (21.1% [30/142 patients] vs. 19.3% [37/192 patients]).  
In obese patients, the dose category of 25-30 mg/kg/day ABW was associated with a 
higher odds of target trough concentration attainment (odds ratio [OR] 5.15, 95% confidence 
interval [CI] 1.69-15.64) (Table 3).  We found similar results for a subset of obese patients 
(n=146) with trough level measurements obtained within 30 minutes of the next vancomycin 
dose (OR 5.0, 95% CI 1.07–23.29).  Additionally, in obese patients, the dose category of <10 
mg/kg/day was associated with a lower odds of target trough concentration attainment (OR 
0.19, 95% CI 0.05-0.70)  
In extremely obese patients, the dose category of 20-25 mg/kg/day ABW was associated 
with a higher odds of target trough concentration attainment (OR 6.07, 95% CI 1.01-36.51).  No 
other significant findings were observed. 
 
Discussion 
Clinicians face extreme difficulty when properly dosing vancomycin in obese and extremely 
obese patients.  This is exemplified by the wide range of total daily doses observed in our study 
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patients (500-6000 mg/day).  Almost half of our patients (48%) had subtherapeutic trough 
concentrations.  Data are consistent with most published reports on vancomycin dosing in 
obese patients and ability to achieve “target concentrations.”15-17  In a small study that included 
37 obese patients, 57% had trough levels <15 mg/L.17  In a multicenter study, 99% (252/254 
patients) of overweight and obese patients did not receive the recommended vancomycin dose 
(15 mg/kg/dose).15  Underdosing vancomycin is a serious concern, as it can lead to inadequate 
serum vancomycin concentrations and poor penetration at the site of infection, development of 
resistance, and potentially poor clinical outcomes.8, 10  In our study, in obese patients, doses <10 
mg/kg/day were associated with a lower odds of target trough attainment. 
We found that the standard vancomycin dose (~30 mg/kg/day) may be appropriate in 
obese patients.  Previous studies have demonstrated that while obese patients required higher 
total daily doses than normal-weight patients, no significant differences in weight-based daily 
doses were required to reach target vancomycin concentrations.12, 18  In both of these small 
studies, the standard dose of ~25-30 mg/kg/day was required to achieve target trough 
concentrations in both normal-weight and obese patients.  However, both of these studies 
included young patients (aged 25-40 years) with good renal function.  In our study, over 50% of 
our cohort were aged 65 years or older.  Most patients (68%) had reduced renal function.  This 
may explain why most patients in our study were dosed every 12-24 hours, despite 
recommendations that vancomycin be dosed more frequently in obese patients (every 8 hours) 
due to altered pharmacokinetic parameters, including a shorter half-life and increased 
clearance.12, 18   
We also found that extremely obese patients may require lower weight-based daily 
doses (20-25 mg/kg/day) than obese patients.  A single-center retrospective study found that a 
group of patients treated according to a revised protocol (n=74) using lower doses (10 mg/kg 
every 12 hours or 15 mg/kg every 24 hours) had improved attainment of target trough 
concentrations compared with a group of patients treated according to an original protocol 
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(n=64) using standard doses (15 mg/kg every 8-12 hours), with 56% attainment in the revised 
protocol group versus 36% in the original protocol group.16  As expected, the mean dose 
administered was lower in the revised protocol group compared to the original protocol group 
(19 vs. 34 mg/kg/day).  Patients in the revised protocol group had a higher mean BMI (~44 
kg/m2) than patients in the original protocol group (~39 kg/m2).  It is therefore likely that more 
patients in the revised protocol group met extremely obese BMI criteria (BMI ≥ 40 kg/m2) than in 
the original protocol group, which may partly explain why patients treated according to the 
revised protocol had a higher percentage of target trough attainment despite using lower doses.   
Almost half of our patients were dosed at the standard dose of 1000 mg every 12 hours.  
Despite the introduction of the updated vancomycin dosing recommendation in 2009,8 a greater 
proportion of patients received the standard vancomycin dose in our study after 2009 compared 
with before 2009 (36.8% from 2002–2009 vs. 46.8% from 2009–2012), although the difference 
was not significant.  Moreover, about 20% of patients achieved target trough concentrations 
before and after introduction of these guidelines.  Among those who did achieve target trough 
concentration attainment (67 patients), the most frequent dose was the standard dose (2000 
mg/day) in both obese and extremely obese patients.  This is in contrast to a recent prospective 
pharmacokinetic study in extremely obese patients, in which dosing simulations indicated that 
much higher doses (4000-5000 mg/day) were necessary for a high probability of target 
attainment.20  However, that study also found that patients with lower renal function may require 
lower doses. Our results suggest that the standard dose of vancomycin may be appropriate at 
least initially in obese and extremely obese elderly patients.  If the standard dose is used 
initially, it is important to make dosage adjustments promptly based on therapeutic drug 
monitoring.  Recent evidence suggests obtaining two serum vancomycin concentrations in 
obese patients to improve target trough attainment.21 
There are several limitations to our findings.  We only assessed trough levels associated 
with initial empiric vancomycin dosing.  We did not assess changes in vancomycin dose or 
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trough concentrations later in therapy.  Therefore, results may not extend to levels beyond this 
period. We cannot ensure that troughs remained at the levels we observed later in therapy.  
Moreover, as obese patients show an increased volume of distribution and clearance, 
vancomycin may not have been at steady state.  Additionally, we did not assess the impact of 
loading doses, as the first dose was only higher than subsequent doses in < 5% of our patients, 
and this dose was often well below the recommended loading dose of 25-30 mg/kg.   
As vancomycin has a half-life of 5-8 hours, collection of a level within 2 hours before the 
next dose may not reflect a true trough level, therefore leading to misclassification of the trough 
as target, subtherapeutic, or supratherapeutic.  Ideally, a trough level should be measured just 
before the next dose; however, this is not always feasible in clinical practice.8  This is 
exemplified by the fact that by using our “relaxed” criteria of collection of a level within 2 hours 
(and also relaxed acute kidney injury criteria), only ~10% of our original vancomycin-treated 
cohort of over 2500 patients met inclusion criteria.  However, we did find similar results in a 
subset of obese patients with a trough level obtained within 30 minutes of the next vancomycin 
dose.  
Due to the retrospective nature of this study, multiple serum vancomycin concentrations 
and MICs were not available for all patients, thus precluding our ability to calculate AUC/MIC 
ratios.   As the purpose of trough measurement is to serve as a surrogate of AUC, this is a 
major limitation of our study. Our study, however, reflects real-world clinical practice, where it is 
often infeasible to calculate AUC/MIC ratios.  Many busy clinicians lack the time for collection of 
multiple levels and/or the training needed for subsequent AUC/MIC calculation. 
As the focus of our study was to evaluate empiric vancomycin dosing in obese and 
extremely obese patients, we did not assess outcomes or toxicity.  We assumed that a trough 
level of 15-20 mg/L was the most optimal target for our obese and extremely obese patients 
based on vancomycin consensus recommendations.8    It is largely unknown which trough level 
is most optimal and associated with the best outcomes in obese and extremely obese patients 
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with MRSA pneumonia.    Furthermore, vancomycin does not display simple pharmacokinetics.  
Therefore, the ability to reach this narrow window may be limited, and it may not be the best 
target for clinical success. 
Our study is further limited by the relatively small sample size.  Finally, the 
generalizability of our findings to general U.S. population may be limited, as our study was 
conducted in a VA population, consisting of mostly older men.  
 
Conclusion 
We contribute to the literature by offering additional consideration on the dosing of vancomycin 
in our real-world cohort of obese and extremely obese patients.  The standard dosing of 
approximately 30 mg/kg/day may be appropriate for obese patients (BMI 30-40 kg/m2) to reach 
target trough levels of 15-20 mg/L.  Extremely obese patients (BMI ≥ 40 kg/m2) may require 
lower weight-based daily doses than obese patients to achieve target vancomycin trough 
concentrations.  Further research is warranted to determine if our results extend to other study 
populations and to determine which vancomycin trough levels are associated with the best 
outcomes in obese and extremely obese patients with MRSA infections. 
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Table 1: Demographics and Clinical Characteristics of the Study Patients by Obese 
Category 
Characteristics 
Obese Group 
(BMI 30-40 kg/m2) 
(n=263) 
Extremely Obese 
Group 
(BMI ≥ 40 kg/m2) 
(n=71) 
P-value 
Age (yrs) 66.7 ± 11.1 64.4 ± 7.6 NS 
Male sex 259 (98.5) 70  (98.6) NS 
Weight (kg)    
     Actual body weight 
102.7 ± 13.1 (range 
72-149) 
139.2 ± 31.1 (range 
89-244) 
<0.05 
     Adjusted body weight 83.9 ± 9.1 97.4 ± 16.4 <0.05 
     Ideal body weight 71.3 ± 7.3 69.5 ± 8.6 NS 
Percentage above ideal body weight 
(%) 
44.1 ± 11.5 99.7  ± 31.0 <0.05 
Body mass index (kg/m2) 33.1 ± 2.4 45.9 ± 7.0 <0.05 
WHO BMI Class   <0.05 
     Obese class 1 (BMI 30.0–34.9 
kg/m2) 
211 (80.2) —  
     Obese class 2 (BMI 35.0– 39.9 
kg/m2) 
52 (19.8) —  
     Obese class 3: extremely obese 
(BMI ≥ 40.0 kg/m2) 
— 71 (100)  
Height (cm) 176.0 ± 8.9 173.8 ± 10.0 NS 
aCrCl at vancomycin initiation 
(ml/min) 
79.4 ± 37.8 (range 
21- 251 
84.8 ± 25.2 (range 
30–140) 
<0.05 
CrCl category   <0.05 
     > 90 ml/min 74 (28.1) 32 (45.1)  
     60-90 ml/min 109 (41.4) 29 (40.9)  
     30-60 ml/min 70 (26.6) 10 (14.1)  
     < 30 ml/min 10 (3.8) 0  
Serum creatinine concentration at 
vancomycin initiation (mg/dL) 
1.2 ± 0.6 1.2 ± 0.5 NS 
BUN at vancomycin initiation (mg/dL) 29.2 ± 19.8 29.0 ± 17.2 NS 
First dose higher than subsquent two 
doses; weight-based dose range if 
higher first dose (mg/kg) 
10 (3.8); 
9–22 
< 5; 
12–15 
NS 
Maintenace vancomycin dose    
    Total daily dose (mg) 
2004.6 ± 736.3 
(range 500–4500)  
2306.1 ± 934.4 
(range 750–6000) 
<0.05 
     Weight-based daily dose 
     (mg/kg/day) 
19.7 ± 7.4 (range 
4–44) 
17.0 ±  6.8 (range 
6–46) 
<0.05  
     Standard dose of 1000 mg every 
     12 hours 
118 (44.9) 24 (33.8) NS 
Vancomycin dosing interval    NS 
     Every 8 hours  5 (1.9) < 5  
     Every 12 hours 191 (72.6) 53 (74.7)  
     Every 18 hours 5 (1.9) < 5  
     Every 24 hours 56 (21.3) 12 (16.9)  
15 
 
  
     Every 36 hours < 5 < 5  
     Every 48 hours < 5 < 5  
Vancomycin serum trough 
concentration (mg/L) 
17.0 ± 8.3 (range 
1–46) 
19.7 ± 10.9 (range 
6–55) 
NS 
Data are mean ± SD values or no. (%) of patients unless otherwise specified. 
 
aCaluculated by using the Cockcroft-Gault equation with adjusted body weight. 
 
BMI= body mass index; NS= not signficant; WHO= World Health Organization; CrCl = creatinine 
clearance; BUN = blood urea nitrogen  
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Table 2: Mean Vancomycin Weight-Based Daily Dose in the Obese and Extremely Obese 
Groups by Trough Level 
 Weight-Based Daily 
Dose (mg/kg/day) 
  
Trough Level Category 
Obese Group 
(BMI 30-40 kg/m2) 
(n=263) 
Extremely Obese 
Group 
(BMI  ≥ 40 kg/m2) 
(n=71) 
P-value 
<10 mg/L 17.0  ± 6.2 16.8  ± 5.8 
NS 
 
10-15 mg/L 19.0  ± 7.5 13.0  ± 3.7 <0.05 
15-20 mg/L 20.5  ± 7.2 14.4  ± 5.9 <0.05 
≥ 20 mg/L 21.7  ± 7.5 21.0  ± 7.3 NS 
Data are mean ± SD values. 
 
BMI= body mass index; NS= not signficant 
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Table 3: Odds of Target Trough Attainment (15–20 mg/L) in the Obese and Extremely 
Obese Groups at Various Vancomycin Weight-Based Daily Doses 
Outcome Odds Ratio (95% CI) P value 
Obese Patients (n=263) 
  (BMI 30-40 kg/m2) 
    Target vs. subtherapeutic trough at a 
    vancomycin dose of < 10 mg/kg/day using 
    actual body weight 
0.19 (0.05-0.70) <0.05 
    Target vs. subtherapeutic trough at a 
    vancomycin dose of 25-30 mg/kg/day using 
    actual body weight 
5.15 (1.69-15.64) <0.05 
Extremely Obese (n=71) 
  BMI ≥ 40 kg/m2) 
    Target vs subtherapeutic trough at a 
    vancomycin dose of 20-25 mg/kg/day using 
    actual body weight 
6.07 (1.01 - 36.51) <0.05 
BMI= body mass index; CI= Confidence Interval; NS= not significant 
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Trough obtained at the appropriate time.* 
N=537 
Patients with suspected MRSA pneumonia, BMI 
>30 kg/m2, and treated with vancomycin.  
N=2,565 
• No VAN level obtained or 
level obtained before 
steady state (<3 doses 
before level). (N=1,129) 
Vancomycin trough concentration taken at steady 
state. 
N=1,436 
• Tau1 and Tau2 >4 hr 
difference. (N=475) 
Vancomycin doses given at regular intervals. 
N=961 
• Trough taken >2 hr before 
next VAN dose or time from 
last dose to level >2 hr 
different than average tau 
(average time interval of 
Tau1 and Tau2)*. (N=424) 
Serum creatinine obtained at baseline and at 
vancomycin initiation. 
 N=352 
• SCr not obtained at VAN 
initiation (day of or day 
prior to VAN treatment 
initiation date). (N=25) 
• SCr not obtained at 
baseline (7 to 2 days prior 
to VAN treatment initiation 
date). (N= 160) 
• SCr change of >0.5 mg/dL 
or >50% between baseline 
and VAN initiation. (N=16) 
• Height < 4 ft 3 inches. 
(N=2)** 
No evidence of acute kidney injury. 
N=336 
Obese 
N=263 
(BMI 30-40 kg/m2) 
Extremely Obese 
N=71 
(BMI >40 kg/m2) 
 
Excluded 
Height > 4 ft 3 inches  
N=334 
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Figure 1. Diagram of the study cohort identification process. *Patients were included if they had 
an appropriately collected through level.  This was defined as a trough that was measured < 2 
hours before the next vancomycin dose or within 2 hours of the average interval between the 2 
prior vancomycin doses.  To avoid not including patients in whom a next dose was never given 
or was given late, we also defined an appropriate trough as one in which the time from the last 
dose before the level to the level was < 2 hours different that the average tau (the average 
interval between the 2 prior vancomycin doses). **Patients who were shorter than 4 ft 3 inches 
were likely amputees since this is a Veteran population.  To increase the generalizability to the 
general United States population, patients under this minimum height were exlcuded. BMI= 
body mass index; MRSA= methicillin-resistant Staphylococcus aureus; VAN= vancomycin; SCr= 
serum creatinine concentration 
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Figure 2. Trough level attainment by obese category. No significant difference by obesity 
category. BMI= body mass index. 
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Figure 3. Histogram of total daily dose distribution for patients who achieved target trough 
concentrations (15–20 mg/L) by obese category. BMI= body mass index. 
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